Occam Places Kimberly Scearce-Levie as Chief Development Officer of Cajal Neuroscience
Cajal Neuroscience, a biotechnology company integrating human genetics, functional genomics and advanced microscopy to discover novel targets and therapeutics for neurodegeneration, launched in November of 2022 with the completion of a $96 million Series A financing led by The Column Group and Lux Capital, with additional participation from Two Sigma Ventures, Evotec, Bristol Myers Squibb, Alexandria Venture Investments, Dolby Family Ventures and other investors.
Kimberly Scearce-Levie joins Cajal from Denali Therapeutics where, as one of the first two dozen pioneering employees to leave Genentech to start this newco, she was an active ingredient in that company’s marvelous transformation from a private, discovery focused play into a leading CNS clinical stage, publicly traded entity.
At Cajal, Kimberly will partner closely with founding CSO, Ian Peikon, and CEO, Nacho Muñoz-Sanjuán, to play an integral role in shaping Cajal’s translational strategy as it matures from a discovery platform into a product company.
Occam Global is an international life science executive search and leadership advisory firm dedicated to building management teams for innovative companies in the biotech, techbio, life sciences, and venture capital sectors. Our firm’s unique strength lies in our seamless access to elite talent, proven expertise in aligning exceptional business and scientific leaders with optimal opportunities, and a steadfast dedication to creating meaningful industry impact, guided by elevated ethics and enlightened aggression. Trusted by entrepreneurs, investors, and corporations worldwide, Occam Global is recognized as the premier partner for executive search and recruitment in the life sciences. Our success is rooted in establishing trust, cultivating and valuing relationships, and committing to serve as forthright and good-humored partners in realizing extraordinary ambitions.